Skip to main content
Signal8

ENDONOVO THERAPEUTICS, INC. (ENDV)

Endonovo Therapeutics, Inc., a biotechnology company, specializes in the development, manufacturing, and distribution of non-invasive electroceutical medical devices designed for regenerative medicine applications. The company's primary offering is SofPulse, an advanced non-invasive therapeutic device that employs electroceutical technology. SofPulse is engineered to provide palliative relief for various conditions, including soft tissue injuries, chronic wounds, and post-operative pain and edema. Beyond these applications, Endonovo's electroceutical medical device is also utilized in treating a broad spectrum of other ailments. These include inflammation, various types of wounds, cardiovascular diseases, chronic kidney and liver disorders (such as non-alcoholic steatohepatitis), peripheral artery diseases, and ischemic stroke. Furthermore, its technology is deployed in managing central nervous system disorders like traumatic brain injury, acute concussions, post-concussion syndrome, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and maintains its headquarters in Woodland Hills, California.

Sector: Electromedical & Electrotherapeutic Apparatus

Industry: Biotechnology

Endonovo Therapeutics, Inc. logo

Endonovo Therapeutics, Inc.

OTC:ENDVHealthcare
Mkt Cap-
Float240.02M
O/S318.75M
Inst Own-
Dilution
Historical Data
DateOpenHighLowCloseVolume
Key Metrics
Market Cap--
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership--

based on 318.75M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeOTC
CountryUSUS
IPO DateNov 15, 2012
Shares Outstanding318.75M
Float240.02M
Company Overview

Endonovo Therapeutics, Inc., a biotechnology company, specializes in the development, manufacturing, and distribution of non-invasive electroceutical medical devices designed for regenerative medicine applications.

The company's primary offering is SofPulse, an advanced non-invasive therapeutic device that employs electroceutical technology. SofPulse is engineered to provide palliative relief for various conditions, including soft tissue injuries, chronic wounds, and post-operative pain and edema. Beyond these applications, Endonovo's electroceutical medical device is also utilized in treating a broad spectrum of other ailments. These include inflammation, various types of wounds, cardiovascular diseases, chronic kidney and liver disorders (such as non-alcoholic steatohepatitis), peripheral artery diseases, and ischemic stroke. Furthermore, its technology is deployed in managing central nervous system disorders like traumatic brain injury, acute concussions, post-concussion syndrome, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and maintains its headquarters in Woodland Hills, California.

Leadership

Alan Brian Collier

Chairman & Chief Executive Officer

Don Calabria

Vice President of Operations

Garry Michael Kann

Head of Corporate Development

Ira Weisberg

President & Chief Commercial Officer of Medical Division

Employees

1

Country

US

Sector

Healthcare

Website

endonovo.com

Analyst Coverage
No analyst coverage for this companyNo ratings, price targets, or covering firms on file.
Insider Trades
No insider transactions for this companyForeign private issuers and non-reporting entities don't file Form 4/5.
Shareholders
--
Institutional
(0)
--
Insiderⓘ
(0)
--
5%+ Owners
(0)
--
Unattributed (incl. retail)ⓘ
Sources:
52-Week Range
Volume
Average Daily Volume225.47K

30d Avg

225.47K

60d Avg

521.41K

90d Avg

727.28K

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...